Related references
Note: Only part of the references are listed.Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano et al.
BLOOD (2014)
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
Tommaso Rondelli et al.
HAEMATOLOGICA (2014)
A Humanized Antibody That Regulates the Alternative Pathway Convertase: Potential for Therapy of Renal Disease Associated with Nephritic Factors
Danielle Paixao-Cavalcante et al.
JOURNAL OF IMMUNOLOGY (2014)
Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis
Tomoki Maekawa et al.
JOURNAL OF IMMUNOLOGY (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PEGylated drugs in rheumatology-why develop them and do they work?
Thomas McDonnell et al.
RHEUMATOLOGY (2014)
Crosstalk between the coagulation and complement systems in sepsis
Florea Lupu et al.
THROMBOSIS RESEARCH (2014)
Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria
Lucia Gargiulo et al.
BLOOD (2013)
A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT
Peter M. Krawitz et al.
BLOOD (2013)
New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties
Hongchang Qu et al.
IMMUNOBIOLOGY (2013)
Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties
Christoph Q. Schmidt et al.
JOURNAL OF IMMUNOLOGY (2013)
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Daniel Ricklin et al.
JOURNAL OF IMMUNOLOGY (2013)
Complement in Immune and Inflammatory Disorders: Therapeutic Interventions
Daniel Ricklin et al.
JOURNAL OF IMMUNOLOGY (2013)
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
Antonio M. Risitano et al.
BLOOD (2012)
Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
Antonio M. Risitano
IMMUNOBIOLOGY (2012)
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
Julien Zuber et al.
NATURE REVIEWS NEPHROLOGY (2012)
Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
Ilene C. Weitz et al.
THROMBOSIS RESEARCH (2012)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard J. Kelly et al.
BLOOD (2011)
Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view
Lucio Luzzatto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans
Andreas Barratt-Due et al.
JOURNAL OF IMMUNOLOGY (2011)
PEGylation of therapeutic proteins
Simona Jevsevar et al.
BIOTECHNOLOGY JOURNAL (2010)
Anovel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement
Margaret A. Lindorfer et al.
BLOOD (2010)
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis
Robert Silasi-Mansat et al.
BLOOD (2010)
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis
Ioannis Kourtzelis et al.
BLOOD (2010)
Synthetic therapeutic peptides: science and market
Patrick Vlieghe et al.
DRUG DISCOVERY TODAY (2010)
Paroxysmal nocturnal hemoglobinuria and eculizumab
Lucio Luzzatto et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
Anita Hill et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
Dominique Helley et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Molecular Intercommunication between the Complement and Coagulation Systems
Umme Amara et al.
JOURNAL OF IMMUNOLOGY (2010)
Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1
Osama A. Hamad et al.
JOURNAL OF IMMUNOLOGY (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Paroxysmal Nocturnal Hemoglobinuria -- Hemolysis before and after Eculizumab.
Antonio M. Risitano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2009)
Eculizumab for paroxysmal nocturnal haemoglobinuria
Charles Parker
LANCET (2009)
Paroxysmal nocturnal hemoglobinuria:: natural history of disease subcategories
Regis Peffault de Latour et al.
BLOOD (2008)
Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases
R. A. Brodsky et al.
BONE MARROW TRANSPLANTATION (2008)
Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets
O. A. Hamad et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
BLOOD (2007)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Complement-targeted therapeutics
Daniel Ricklin et al.
NATURE BIOTECHNOLOGY (2007)
Factor H-mediated cell surface protection from complement is critical for the survival of PNH erythrocytes
Viviana P. Ferreira et al.
BLOOD (2007)
The structure of OMCI, a novel lipocalin inhibitor of the complement system
Pietro Roversi et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria
Lucia Gargiulo et al.
BLOOD (2007)
Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
Anita Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Complement and coagulation: strangers or partners in crime?
Maciej M. Markiewski et al.
TRENDS IN IMMUNOLOGY (2007)
Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH)
Norimitsu Inoue et al.
BLOOD (2006)
A novel c5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways
Konstantinos Ritis et al.
JOURNAL OF IMMUNOLOGY (2006)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H
ES Reis et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2006)
Diagnosis and management of paroxysmal nocturnal hemoglobinuria
C Parker et al.
BLOOD (2005)
Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata
MA Nunn et al.
JOURNAL OF IMMUNOLOGY (2005)
Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
VM Moyo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
C Hall et al.
BLOOD (2003)
Molecular genetics of paroxysmal nocturnal hemoglobinuria
N Inoue et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones
DJ Araten et al.
LEUKEMIA (2002)